Clinical Trial Update: Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating in vivo PARP-1 expression in breast cancer using the PET tracer 18F-FluorThanatrace.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• 18F-FluorThanatrace

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Breast Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING